Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca, Daiichi Sankyo's Datroway (datopotamab deruxtecan) gains EU approval for first-line unresectable or metastatic triple-negative breast cancer based on Ph3 data
Antibody-drug conjugate, cancer, triple-negative breast cancer, TROP2, first-line treatment - Read more

Pharmanovia licenses IMPACT Therapeutics' oral PARP1/2 inhibitor senaparib for key regions outside China, up to €423.5M ($488M)
Licensing deal, oncology, small molecule, milestone payments, royalties - Read more

Kaigene, Taisho Pharmaceutical sign exclusive Japan licensing deal for KG006, $5M upfront, ~$373M milestones
Licensing deal, autoimmune, antibody, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Pfizer seeks label expansion for Litfulo (ritlecitinib) targeting JAK3 after Ph3 success in nonsegmental vitiligo
Small molecule, autoimmune, JAK inhibitor, vitiligo, ritlecitinib, label expansion - Read more

Regeneron posts biggest quarterly revenue growth since pandemic on booming Dupixent sales
Monoclonal antibody, autoimmune, respiratory, revenue impact, financial - Read more

AbbVie's Skyrizi hits $5.55B quarterly sales, matching Humira's peak despite new competition
Monoclonal antibody, autoimmune, revenue impact, competitive - Read more

Moderna maintains 10% growth target despite Phase 3 norovirus vaccine trial interim analysis miss
mRNA vaccine, infectious disease, financial, operational - Read more

Apnimed raises $192M in upsized IPO to fund sleep apnea pill launch
Sleep apnea, small molecule, clinical-stage, neurology - Read more

Ractigen Therapeutics raises over $31M, advancing saRNA therapeutics and extrahepatic delivery systems
RNA therapeutics, small activating RNA, oncology, neurological, rare disease, clinical-stage - Read more

DBV Technologies raises $50M via ATM program, selling ADSs to RA Capital Management
Late-stage biopharmaceutical, allergy, immunology, clinical-stage - Read more

Trump administration releases $600M for Gavi, reversing halt on childhood immunization funding
Vaccine, infectious disease, financial, operational - Read more

Replimune's (vusolimogene oderparepvec) wins positive adcomm vote for advanced melanoma in Ph1/2 combination trial
Gene therapy, cancer, oncolytic virus, melanoma, PD-1 checkpoint inhibitor, combination therapy - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novo Nordisk's (ziltivekimab) IL-6 inhibitor fails Ph3 trial for atherosclerotic cardiovascular disease with chronic kidney disease
Antibody, cardiovascular, monoclonal antibody, IL-6 inhibitor, atherosclerotic cardiovascular disease, chronic kidney disease - Read more

Karyopharm Therapeutics' Xpovio (selinexor) Ph3 trial misses primary endpoint in TP53 wild-type advanced endometrial cancer
Small molecule, cancer, XPO1 inhibitor, endometrial cancer, multiple myeloma, myelofibrosis - Read more

Bristol Myers Squibb delays Cobenfy, milvexian key readouts to 2027 amid slower trial enrollment
Small molecule, cardiovascular, neurological, financial - Read more

AbbVie Q2 I&I beat disappoints investors, shares drop 4% despite 15% revenue growth
Small molecule, autoimmune, financial, competitive, major transaction - Read more

Daiichi Sankyo shares drop 11% after accounting error reveals $182M missed SG&A expenses
Antibody-drug conjugate, oncology, financial, operational - Read more

Alnylam Pharmaceuticals plunges 30%, losing $12B market value after lowering TTR drug revenue forecast by $200M
RNAi, cardiovascular, financial, competitive - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here